SLC1A4: A Potential Drug Target and Biomarker for Alanine, Serine, Cysteine, and Thronine Transporters

Target Name: SLC1A4

NCBI ID: G6509

SLC1A4

SLC1A4: A Potential Drug Target and Biomarker for Alanine, Serine, Cysteine, and Thronine Transporters

Introduction

SLC1A4 (serine/lysine transporter 1) is a protein that is expressed in various tissues and cells in the human body. It is a member of the SLC family of transporters, which are known for their ability to transport amino acids across cell membranes. SLC1A4 is primarily expressed in the brain, where it is involved in the transport of serine, threonine, and cysteine 鈥嬧?媋cross the blood-brain barrier (BBB).

The Importance of SLC1A4

SLC1A4 plays a critical role in the delivery of amino acids across the BBB. The BBB is a specialized barrier that separates the brain from the blood and is designed to protect the brain from harmful substances. However, it is also selective in allowing certain molecules to enter the brain while keeping others out. The ability of SLC1A4 to transport serine, threonine, and cysteine 鈥嬧?媋cross the BBB is essential for maintaining the health and function of the brain.

SLC1A4 has been implicated in several neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. In these disorders, the disruption of the normal function of SLC1A4 has been implicated in the misfolding and translation of proteins, which can lead to the formation of toxic aggregates that cause damage to the brain.

Potential Therapeutic Applications

SLC1A4 has been identified as a potential drug target for several reasons. Firstly, drugs that can modulate the activity of SLC1A4 have been shown to improve the symptoms of neurological and psychiatric disorders. For example, studies have shown that modulation of SLC1A4 activity can improve the treatment outcomes of Alzheimer's disease, Parkinson's disease, and schizophrenia.

Secondly, SLC1A4 has been shown to play a role in the development and progression of neurodegenerative diseases. The disruption of SLC1A4 has been implicated in the development of neurofibrillary tangles and neuroinclusions, which are hallmarks of neurodegenerative diseases. Therefore, targeting SLC1A4 with drugs that can Modulate its activity may be a promising strategy for the treatment of these disorders.

Thirdly, SLC1A4 has been shown to be involved in the regulation of brain function and its disorders. SLC1A4 has been shown to play a role in the regulation of neurotransmitter release and in the modulation of synaptic plasticity. Therefore, drugs that can modulate SLC1A4 activity may be useful for treating disorders that are characterized by changes in brain function, such as those associated with neurodegenerative diseases.

Molecular Mechanisms

SLC1A4 is a member of the SLC family of transporters, which are characterized by the presence of a single transmembrane protein that consists of an intrinsically disordered N-terminus, a transmembrane segment, and an intracellular cytoplasmic tail. SLC1A4 has a calculated molecular weight of 120 kDa and a pre-expression level of 15.5 kDa.

SLC1A4 is expressed in various tissues and cells, including the brain, heart, liver, and muscle. It is primarily expressed in the brain and is involved in the transport of serine, threonine, and cysteine 鈥嬧?媋cross the BBB. SLC1A4 has been shown to play a role in the regulation of neurotransmitter release and in the modulation of synaptic plasticity.

Drugs that can modulate SLC1A4 activity include inhibitors of serine/lysine transporter (SST), which is a related transporter to SLC1A4, and modulators of the SLC1A4 gene, such as RNA interference

Protein Name: Solute Carrier Family 1 Member 4

Functions: Sodium-dependent neutral amino-acid transporter that mediates transport of alanine, serine, cysteine, proline, hydroxyproline and threonine

The "SLC1A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC1A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets